Evidence map›Paper›PMID 28282246›Full record

ArticleAIDS patient care and STDs2017

Sex, Race, and HIV Risk Disparities in Discontinuity of HIV Care After Antiretroviral Therapy Initiation in the United States and Canada.

Peter F Rebeiro, Alison G Abraham, Michael A Horberg, Keri N Althoff, Baligh R Yehia, Kate Buchacz, Bryan M Lau, Timothy R Sterling, Stephen J Gange

Abstract read
In one paragraph

Article in AIDS patient care and STDs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Relationships Between Patient Race and Residential Race Context With Missed Human Immunodeficiency Virus Care Visits in the United States, 2010-2015.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Peter F Rebeiro1 Vanderbilt University School of Medicine , Department of Medicine, Division of Infectious Diseases, Nashville, Tennessee.
Alison G Abraham2 Johns Hopkins University , Bloomberg School of Public Health, Department of Epidemiology, Baltimore, Maryland.
Michael A Horberg3 Mid-Atlantic Permanente Research Institute , Kaiser Permanente Mid-Atlantic States, Rockville, Maryland.
Keri N Althoff2 Johns Hopkins University , Bloomberg School of Public Health, Department of Epidemiology, Baltimore, Maryland.
Baligh R Yehia4 University of Pennsylvania , Perelman School of Medicine, Department of Medicine, Philadelphia, Pennsylvania.
Kate Buchacz5 Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention , Atlanta, Georgia .
Bryan M Lau2 Johns Hopkins University , Bloomberg School of Public Health, Department of Epidemiology, Baltimore, Maryland.
Timothy R Sterling1 Vanderbilt University School of Medicine , Department of Medicine, Division of Infectious Diseases, Nashville, Tennessee.
Stephen J Gange2 Johns Hopkins University , Bloomberg School of Public Health, Department of Epidemiology, Baltimore, Maryland.

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
NCATS NIH HHS UL1 TR000454NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI094189
6 · The paper itself

Abstract

Disruption of continuous retention in care (discontinuity) is associated with HIV disease progression. We examined sex, race, and HIV risk disparities in discontinuity after antiretroviral therapy (ART) initiation among patients in North America. Adults (≥18 years of age) initiating ART from 2000 to 2010 were included. Discontinuity was defined as first disruption of continuous retention (≥2 visits separated by >90 days in the calendar year). Relative hazard ratio (HR) and times from ART initiation until discontinuity by race, sex, and HIV risk were assessed by modeling of the cumulative incidence function (CIF) in the presence of the competing risk of death. Models were adjusted for cohort site, baseline age, and CD4

Indexed as

Antiretroviral Therapy, Highly ActiveAdultAnti-HIV AgentsBlack or African AmericanBlack PeopleCanadaCD4 Lymphocyte CountCohort StudiesHealthcare DisparitiesHIV InfectionsHumansIncidenceMaleMiddle AgedPatient Acceptance of Health CareProportional Hazards ModelsAnti-HIV Agentsdiscontinuitydisparityinjection drug useNA-ACCORDracialretentionsex

Identifiers

PMID28282246
PMCPMC5359655

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.